Lamitor, tablets 25 mg 30 pcs

Lamitor is an anticonvulsant (antiepileptic) drug.

A blocker of potential-dependent sodium channels.

Causes block of impulse discharges in neuronal culture and inhibits excessive release of glutamate (amino acids that play a key role in the generation of epileptic seizures) along with inhibition of glutamate-induced effector impulses.

Indications

For adults and children over 12 years of age:

For children aged 2 to 12 years, as adjunctive therapy.

Active ingredient

Composition

Tablets

Active ingredient:

Lamotrigine 25 mg

.

How to take, the dosage

The starting dose of Lamitor for adults and children over 12 years of age not taking sodium valproate but taking other isoenzyme-inducing antiepileptic drugs is 50 mg once daily for the first 2 weeks and 100 mg/day (2 doses) for the next 2 weeks. Then the dose should be increased to 200-400 mg/day (in 2 doses).

The starting dose of Lamitor for patients taking sodium valproate in combination with other isoenzyme-inducing antiepileptic drugs is 25 mg every other day for the first 2 weeks and then 25 mg once daily for the next 2 weeks. Then the dose should be increased until optimal therapeutic effect is achieved. The maintenance dose is 100-200 mg (1 or 2 doses).

The starting dose of Lamitor for children 2 to 12 years old not taking sodium valproate but taking other isoenzyme-inducing antiepileptic drugs is 2 mg/kg/day (in 2 doses) for the first 2 weeks and 5 mg/kg/day (in 2 doses) for the next 2 weeks. The maintenance dose is 5-15 mg/kg/day (in 2 doses).

The starting dose of Lamitor for children taking sodium valproate in combination with other isoenzyme-inducing antiepileptic drugs is 0.2 mg/kg 1 time/day for the first 2 weeks, then 0.5 mg/kg 1 time/day for the next 2 weeks. Then the dose should be increased until optimal therapeutic effect is achieved. The maintenance dose is 1-5 mg/kg (1 or 2 doses).

Interaction

Concomitant use with antiepileptic drugs inducing hepatic isoenzymes (phenytoin, carbamazepine, phenobarbital, primidone) increases Lamitor metabolism, which may require increasing its dose.

Sodium valproate, which competes with lamotrigine with respect to liver metabolizing isoenzymes, inhibits its metabolism. There is no evidence that Lamitor can induce or inhibit liver isoenzymes that metabolize other drugs. Lamitor can induce its own metabolism, but this effect is very small and does not cause serious clinical manifestations.

While changes in plasma concentrations of other antiepileptic drugs have been noted in some patients, controlled studies have not confirmed the effect of Lamitor on plasma levels of concomitant antiepileptic drugs. In vitro studies indicate that Lamitor does not compete with other antiepileptic drugs for plasma protein binding sites.

Special Instructions

Information on the use of Lamitor in elderly patients is limited. Therefore, caution should be exercised when prescribing the drug to this category of patients.

If the dose of Lamitor is exceeded, a skin rash may occur (in this case the drug should be discontinued).

In some cases, the drug may cause a severe skin rash (including Stevens-Johnson syndrome). These reactions develop more often in children. Lamitor should be discontinued at the first sign of a rash. The risk of these complications is increased when Lamitor is prescribed concomitantly with sodium valproate and if the dose of Lamitor used exceeds the recommended initial and maximum daily dose.

The drug should be discontinued immediately if a skin rash develops.

When using Lamitor, symptoms of hypersensitivity may develop (in some cases up to and including death), such as fever, malaise, cold symptoms, drowsiness, lymphadenopathy, facial edema, and in very rare cases, liver dysfunction, hematopoiesis (leukopenia and thrombocytopenia). In most patients, these symptoms disappear after discontinuation of Lamitor.

If rash, chills, cold symptoms, drowsiness, worsening seizure control occur during use (especially in the first month), liver function tests, renal function tests, and blood clotting should be monitored.

If Lamitor is abruptly withdrawn, seizures may become more frequent. The dose of Lamitor should be reduced gradually over 2 weeks.

In patients with impaired renal function, accumulation of the metabolite as glucuronide should be expected in the terminal stage of the disease. Therefore, caution should be exercised when prescribing in these patients.

Impact on driving and operating machinery

The ability to drive motor vehicles and operate moving machinery while taking Lamitor is decided on an individual basis taking into account the clinical situation.

Contraindications

Hypersensitivity; marked liver function abnormalities.

Side effects

CNS disorders: dizziness, headache, drowsiness, sleep disturbance, increased fatigue.

Digestive system disorders: nausea.

Allergic reactions: maculopapular skin rash (2%), most often observed in the first 4 weeks after the start of treatment and disappears after discontinuation of the drug. In some cases – Stevens-Johnson syndrome, angioedema, toxic epidermal necrolysis.

Side effects when using Lamitor as adjunctive therapy to standard antiepileptic drugs

CNS side effects: dizziness, headache, somnolence, impaired balance, increased fatigue, irritability, aggressiveness, tremor, confusion.

Visual organs: diplopia, visual acuity disorders.

Hematopoietic system disorders: neutropenia, leukopenia.

Digestive system disorders: nausea, vomiting, dyspeptic symptoms.

Overdose

Symptoms: nystagmus, ataxia, dizziness, drowsiness, headache, nausea, unconsciousness, coma.

Treatment: gastric lavage, administration of activated charcoal. If necessary, symptomatic therapy is carried out.

Pregnancy use

The drug should not be administered during pregnancy and lactation unless the expected benefits of therapy to the mother exceed the potential risk to the fetus and child.

Similarities